Phobic Disorders Clinical Trial
— CTRLSTRESSOfficial title:
Virtual Reality and Concept of Control in the Treatment of Acrophobia by Exposure to Virtual Environments: Comparative Test
Virtual reality is currently used as a therapeutic strategy in common phobia as agoraphobia or acrophobia, since it permits to have a better control (on occurrence of events or on the environment) during the therapy than in "in vivo" therapy. Our hypothesis here is that we can improves the therapeutic effects of the virtual exposure by giving control to acrophobic patients during their exposure.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | July 2017 |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria of all subjects: - 18 to 60 years old - Male or female - All subjects will be fluent in French. - Fully informed and freely given, signed Informed consent in written form. - Patient / Subject affiliated or beneficiary of a social/health security insurance. Inclusion criteria for acrophobic patients: - Patients not hospitalized suffering from acrophobia (according to DSM-IV, APA 2000). - Patients receiving pharmacotherapy (anxiolytics, hypnotics, etc.) may be included provided they are stabilized on treatment for at least 8 weeks. - Score inferior to 6 at the Behavioural Avoidance Test Inclusion criteria for healthy volunteers: - People not hospitalized showing no sign of acrophobia. - Score superior or equal to 10 at the Behavioural Avoidance Test. Exclusion Criteria for all subjects: - Pregnant woman (urine and blood ß -HCG test) or lactating (contraindication to PET-scan). - Women of childbearing potential without effective contraception (contraindication to PET-scan). - Subject participating in another research evaluating other treatments including a period of exclusion still ongoing. - Persons under guardianship and adults subject submitted to a measure of legal protection or unable to consent. - Persons deprived of their liberty by a judicial or administrative decision, those hospitalized without consent under Articles L. 3212-1 and L. 3213-1 that do not fall under the provisions of Article L. 1121-8 and admitted to a health or social institution for purposes other than research. - People with a non-stabilized diabetes (contraindication to PET-scan). - Addictions to alcohol or drugs. - Persons suffering from claustrophobia. - Contraindications to fMRI. - People with hearing loss. - Strong visual impairment (> 5 diopters) not corrected by contact lenses. Exclusion criteria for acrophobic patients: - Patients continuing psychotherapy. - Patients suffering from other neurological disorders or comorbid psychiatric diseases than acrophobia. - Patients suffering from severe organic disorders that could disable or disrupt the therapeutic process. - The concomitant drugs at inclusion should not be modified or discontinued during the study. - No psychotherapy should be initiated during the study. Exclusion criteria for healthy volunteers: - Subjects with a known psychiatric or neurological disorders, diagnosed for depression, with emotional disorders affecting their perception of the environment, or taking a medication that may affect the auditory and visual perception, concentration or emotions. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Service hospitalo-universitaire de psychologie médicale de psychiatrie d'adultes du Pr Lançon - CHU Marseille | Marseille |
Lead Sponsor | Collaborator |
---|---|
Qualissima | France: Centre National de la Recherche Scientifique |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Behavioural Avoidance Test (BAT) | Objective measure of behavior scored on 10 points in response to a virtual environment representing a situation feared by acrophobic patients. This virtual environment is a flat landscape with a platform overlooking a canyon of 800 meters. | 1 year (4 times) | No |
Secondary | Brain activity (functional MRI) | Anatomical and functional : brain activity in several cortical and subcortical areas with fMRI (BOLD signal intensity) | 12 weeks (2 times) | No |
Secondary | Synaptic activity (PET-scan) | Metabolic and functional : synaptic activity with PET scanner | 12 weeks (2 times) | No |
Secondary | Cognitive measurements | Attentional bias (DOT test) | 12 weeks (2 times) | No |
Secondary | Cognitive measurements | Emotional valence (emotional congruence task) | 12 weeks (2 times) | No |
Secondary | Cognitive measurements | Questionnaire on acrophobia (AQ: Acrophobia Questionnaire) | 1 year (4 times) | No |
Secondary | Cognitive measurements | Questionnaire on acrophobia (ATHQ: Attitude Towards Heights Questionnaire) | 1 year (4 times) | No |
Secondary | Cognitive measurements | Questionnaire on anxiety (STAI: Spielberger Trait Anxiety Inventory) | 1 year (4 times) | No |
Secondary | Cognitive measurements | Questionnaire on depression (BDI: Beck Depression Inventory) | 1 year (4 times) | No |
Secondary | Quality of life | Quality of Life (SF-12: Medical Outcome Study Short Form) | 1 year (4 times) | No |
Secondary | Cognitive measurements | During the 8 sessions of exposure to virtual reality: Questionnaires on anxiety (SUD: Subjective Unit of Discomfort) | 10 weeks (8 times) | No |
Secondary | Cognitive measurements | During the 8 sessions of exposure to virtual reality: Progression recorded and time to progression from one environment to another during sessions (number of environments completed, time of execution, others ..) | 10 weeks (8 times) | No |
Secondary | Ergonomy | During the 8 sessions of exposure to virtual reality: Questionnaire on the applicability / realism / ergonomy (PQ: Questionnaire on the state of Presence). | 10 weeks (8 times) | No |
Secondary | Psychophysiological | During the 8 sessions of exposure to virtual reality: Psychophysiological objective measurements during exposure to virtual reality (electrodermal activity, electrocardiography, breathing rate) | 10 weeks (8 times) | No |
Secondary | Adverse events | Assessment and description of all the occurrence of adverse events during the study. | 1 year | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01963806 -
ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder
|
N/A | |
Completed |
NCT00121069 -
Study of Escitalopram in the Treatment of Specific Phobia
|
Phase 2/Phase 3 | |
Recruiting |
NCT03653923 -
Neurophysiological Correlates of Exposition Therapy in Spider Phobia
|
N/A | |
Completed |
NCT00184106 -
RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo
|
Phase 4 | |
Completed |
NCT00051220 -
Treatment for Specific Phobias in Children
|
Phase 1/Phase 2 | |
Completed |
NCT02387047 -
Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly
|
N/A | |
Completed |
NCT02310152 -
Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)
|
N/A | |
Completed |
NCT00000370 -
Treatment of Social Phobia
|
N/A | |
Completed |
NCT03012035 -
The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants
|
N/A | |
Completed |
NCT02007694 -
Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03188575 -
Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT
|
N/A | |
Completed |
NCT02432703 -
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
|
Phase 2 | |
Terminated |
NCT01574014 -
Glucocorticoid Treatment for Social Phobia
|
Phase 2 | |
Completed |
NCT00734422 -
Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02336802 -
Threat-Avoidance Learning in Anxiety Patients
|
N/A | |
Completed |
NCT01361074 -
In Vivo Versus Augmented Reality Exposure for Small Animal Phobia
|
N/A | |
Completed |
NCT00104195 -
A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions
|
Phase 1 | |
Completed |
NCT00035412 -
St. John's Wort Versus Placebo in Social Phobia
|
Phase 2 | |
Completed |
NCT00128401 -
Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia
|
Phase 2 | |
Terminated |
NCT01623583 -
Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias
|
Phase 4 |